ClinicalTrials.gg
CompletedNCT06629545Updated Oct 8, 2024

The Efficacy of Two Different Irrigation Methods on PGE2, NO and IL-6 Levels

An interventional study of irrigation activation with PUI and irrigation with sonic activation in Apical Periodontitis and Inflammatory Markers, sponsored by Istanbul Medipol University Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Istanbul Medipol University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Aug 2023, registered Oct 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Today, debates about the effectiveness of Passive Ultrasonic Irrigation (PUI) and Sonically Activated Irrigation (SAI) techniques used to increase the success of endodontic treatment in chronic apical periodontitis (AP) are still ongoing.

In this study, the effectiveness of PUI and SAI systems was investigated in AP patients with similar infection burden and periapical lesion size (PLS) based on changes in prostaglandin E2 (PGE2), nitric oxide (NO) and interleukin-6 (IL-6) levels, which are important biomarkers of inflammatory response in gingival crevicular fluid (GCF) samples.

The study was planned as a single-center cross-sectional analytical study. A total of 60 patients with AP requiring root canal treatment [PUI (n:30) and SAI (n:30)] and 30 healthy controls were included in the study between January and June 2024. Demographic characteristics of the patients as well as clinical and radiographic findings (PLS and PAI score) were recorded. GCF (preGCF), PGE2, NO and IL-6 levels were measured in all participants before irrigation. The same procedure was repeated in GCF samples 1 week after treatment (postGCF), except for the control group. In addition, 1st order most commonly seen bacteria (FMCB) typing was performed on swab samples taken from the root canals of the patients.

Read the detailed description

The diagnosis was established according to the patient's history, clinical inspection including palpation, tenderness to percussion, pulpal sensitivity testing, and radiographic examination. Demographic characteristics of the participants (age, gender, chronic disease status, etc.) as well as clinical and radiographic findings [pain level, number of crowns (NC), number of fillings (NF), number of root canal fillings (NRC), and number of missing teeth (NMT)] were recorded. Panoramic and periapical dental radiographs were taken. The presence of radiolucent images associated with the periapical region and radiographic bone loss were evaluated. Radiographs were examined with the help of Kodak Dental Imaging Software. The presence of periapical radiolucency without periodontal disease was considered sufficient criteria for the diagnosis of AP. The largest diameter of the lesion was measured on preoperative periapical radiographs and recorded as periapical lesion size (PLS). In addition, periapical index (PAI) score defined by Ørstavik et al (Ørstavik et al., 1986) and abscess scoring based on the periapical index (AS-PAI) were recorded for patients with AP. AS-PAI was determined as follows: AS-PAI-0 if PAI\<5, AS-PAI-1 if only 1 tooth with PAI 5 and AS-PAI-2 if >2 teeth with PAI 5

02

Conditions studied

  • Apical Periodontitis
  • Inflammatory Markers

Keywords

  • apical periodontitis
  • passive ultrasonic irrigation
  • Sonically Activated Irrigation
  • Gingival crevicular fluid
  • PGE
  • IL-6
03

In context

Periapical Periodontitis

256 studies on the registry are indexed under Periapical Periodontitis; 65 are open to participants now.

This study's enrollment of 90 is above the median of 60 across 222 interventional studies indexed under Periapical Periodontitis.

Browse Periapical Periodontitis studies →

Lead sponsor

Istanbul Medipol University Hospital is the lead sponsor of 365 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For control group

  • People who come for a check-up, are healthy in terms of dental and periodontal health, do not have any systemic acute or chronic disease (such as infection, kidney disease, cardiovascular disease, inflammatory and rheumatic disease, diabetes and local or widespread tissue damage) and have similar values in terms of gender, age and weight to the study groups, For experimental groups
  • Being systemically healthy,
  • Patients between the ages of 18-65,
  • Those having a PAI score of 3-5 For both study and control groups
  • The volunteer wishes to participate in the research by signing the \&amp;#39;Informed Consent Form\&amp;#39;.

Exclusion criteria

Exclusion Criteria:

  • Those who have used nonsteroidal anti-inflammatory drugs and/or immunosuppressive drugs, steroids in the last 48 hours as this may affect the test results, and those who have a history of using high doses of biotin vitamin as this may affect the test results,
  • Those who were either pregnant, lactating, morbidly obese, presence of malignancy, presence of concomitant infection other than AP, presence of acute or chronic inflammatory disease,
  • Those with periodontal disease (with periodontal pockets and attachment levels exceeding 4 mm.),
  • Those having inadequate crown structures for isolation with a rubber dam,
  • Those with a history of previous endodontic treatment.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Passive ultrasonic irrigation

    The irrigation solution was agitated by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device.

    Other: irrigation activation with PUI

  • Experimental
    Sonic activated irrigation

    The irrigation solution was agitated by a suitable-size activator tip (#25/.04) attached to an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA).

    Other: irrigation with sonic activation

  • No intervention
    Control group

    Pre-treatment GCF (preGCF) samples were collected for all participants

Interventions

  • Otherirrigation activation with PUI

    The irrigation solution was used by adapting an ultrasonic tip (IRRI S 21/25; VDW, Munich, Germany) to an ultrasonic device. The power setting of the ultrasonic device was 30% (VDW Ultra; VDW, Munich, Germany). The tip was activated a total of three times, with each cycle lasting 20 s and involving the use of 1 ml of 2.5% NaOCl. Then, 2 ml of 17% EDTA solution was activated for 1 min as describe above. The ultrasonic tip was placed 1 mm behind the working length without touching the canal walls.

  • Otherirrigation with sonic activation

    A suitable-size activator tip (#25/.04) attached to an EndoActivator sonic handpiece (Dentsply Tulsa Dental Specialties, Tulsa, OK, USA) was inserted into the canal 1 mm short of the working length. 3 ml of 2.5% NaOCl solution was activated in three periods of 20 s (1 ml of 2.5% NaOCl in each cycle). Then, the same procedure was repeated with 2 ml of 17% EDTA solution.

06

What researchers measure

Primary outcomes

  1. ELISA Analysis of Biochemical Parameters

    ELISA assay was performed to measure preGCF and postGCF-PGE2, NO and IL-6 levels

    Time frame: Up to 36 weeks

Secondary outcomes

  1. Genomic DNA isolation and measurement of DNA concentration

    Pretreatment bacteria number and bacteria species of samples taken from root canals measured via PCR and Sanger sequencing

    Time frame: Up to 36 weeks

07

Study locations

1 site
  • Istanbul Medipol University Faculty of Dentistry
    Istanbul, Esenler, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — all collected IPD, all IPD that underlie results in a publication

Supporting information: Study protocol, Statistical analysis plan

Time frame: starting 6 months after publication

Access criteria: The investigators want to share IPD including all ddPCR and ELISA results with all researchers

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06629545
Responsible party
Seyda Ersahan, DDS, PhD (Seyda Ersahan, Clinical Associate Professor, Istanbul Medipol University Hospital) — Principal investigator
First posted
Oct 8, 2024
Start date
Aug 2, 2023
Primary completion
Apr 1, 2024
Completion
Apr 1, 2024
Last update
Oct 8, 2024

Study contacts

Seyda Ersahan, Assoc.Prof.
principal investigator · Medipol University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion